Modeling Luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in Luminal disease

Conclusions: We propose that response to combination endocrine/EGFR inhibitor therapies in heterogeneous Luminal cancers may improve long-term survival in patients whose primary tumors have been preselected for appropriate biomarkers, including ER, PR, CK5 and EGFR.

http://breast-cancer-research.com/content/16/4/418

Source: Breast Cancer Research - August 13, 2014 Category: Cancer & Oncology Authors: Aaron KnoxAllison ScalingMauricio PintoBrian BliesnerJames HaughianHany Abdel-HafizKathryn Horwitz Source Type: research